scholarly journals Exploring Nanoemulsions for Prostate Cancer Therapy

Drug Research ◽  
2021 ◽  
Author(s):  
Sushmita Srivastava ◽  
Md. Faheem Haider ◽  
Afroz Ahmad ◽  
Usama Ahmad ◽  
Muhammad Arif ◽  
...  

AbstractProstate carcinoma is typical cancer. It is the second most common cancer globally. The estimated new cases in 2020 was 191 930 and estimated deaths was 33 330. Age, family history, & genetic factors are major factors that drive prostate cancer. Although, for treating metastatic disease, the major therapies available are radiation,bisphosphonate, and palliative chemotherapy. But the major drawback is therapy is disease-driven and later becomes metastatic and requires treatment. The ability to revolutionize cancer treatment by major targeting vehicles via the exploration of nanoemulsion suggests a potential for cancer treatment. The unique property of a biphasic liquid dosage form called nanoemulsion to reach leaky tumor vasculature is due to its nano-meter oil-droplet size of 20–200 nm. Recent reporting on nanoemulsions disclose their embracing and lay alternative for re-purposing herbal and synthetic drugs and their combination especially for targeting prostate cancer formulating an obtainable nanomedicine. So, this article emphasizes the use of nanoemulsions incorporating therapeutic agents for successful and targeted delivery for prostate cancer.

This effort was under taken during the tenure of a postgraduate study by Firew Admasu at Jimma University, Jimma Referral Hospital on the case of prostate cancer while discussing with medical doctors about symptom stages, risk factors, diagnosis, complications and its treatments during visiting a surgery patient and organizing while giving the course of human anatomy and physiology at Dilla University. Background: Based on human anatomy and physiology, prostate is a small gland, found only in men, located between penis and bladder, surrounds the urethra and used to produce a thick white fluid that creates semen when mixed with sperm produced by testicles and prostate cancer occurs if abnormal cells develop in the prostate gland to multiply in an uncontrolled mode. Prostate cancer is the most common cancer in men, develops slowly, there may no signs and symptoms appear until prostate become large enough to affect urinary tube and it is a common condition worldwide that have varying incidence and mortality, and it is the third most common cancer in men of developed countries. Objectives: The main objective is to assess epidemiology of prostate cancer and its associated risk, specifically, to identify the major factors that increased chance of developing prostate cancer, to point out the main later stages symptoms, complications, prevention or reduce the risk, detection and diagnosis of prostate cancer. Methods: The assessment of the epidemiological investigations of surveillance and descriptive studies on the distribution and determination of the characteristics of prostate cancer includes major factors, symptoms, complications, preventions, detection and diagnosis methods. Results: The major factors strongly associated to increased chance of developing prostate cancer includes increasing age, positive family history (genetics), nutrition (obesity) and lifestyle. The later stages symptoms and complications include sudden need to urinate but difficulty with discomfort to urinate, bloody urine or semen, and dysfunction of erectile muscle. The risk of prostate cancer can be prevented or reduced by feeding a healthy diet, nutrition, doing physical exercise, and keeping our weight a healthy and it can be detected and diagnosed by a blood test and/or physical examination test and biopsy. In addition, different types of treatment choices at the early-stage of prostate cancer are advisable such as active surveillance, surgery, and radiation therapy are the standard therapy and difficulty to control urine may be happen after surgery due to splitting of sphincter muscle and erectile dysfunction. Therefore, this study and intervention efforts in the region should be focused on understanding its prevention methods, later stages symptoms, differences in treatment, stage at diagnosis, and early detection by socioeconomic status.


2019 ◽  
Vol 7 (12) ◽  
pp. 109
Author(s):  
Travis P. Green ◽  
Jose Saavedra-Belaunde ◽  
Run Wang

The majority of sexual health research has focused on erectile dysfunction following prostate cancer treatment. Ejaculatory and orgasmic dysfunction are significant side effects following the treatment of prostate cancer. Orgasmic dysfunction covers a range of issues including premature ejaculation, anorgasmia, dysorgasmia, and climacturia. This review provides an overview of prevalence and management options to deal with orgasmic dysfunction. A Medline Pubmed search was used to identify articles relating to these problems. We found that orgasmic dysfunction has a very large impact on patients’ lives following prostate cancer treatment and there are ways for physicians to treat it. Management of patients’ sexual health should be focused not only on erectile dysfunction, but on orgasmic dysfunction as well in order to ensure a healthy sexual life for patients and their partners.


2018 ◽  
Vol 22 (11) ◽  
pp. 1030-1038 ◽  
Author(s):  
Nikita V. Suvorov ◽  
Alexey E. Machulkin ◽  
Anna V. Ivanova ◽  
Alexander M. Popkov ◽  
Elizaveta A. Bondareva ◽  
...  

Prostate cancer is an extremely common cancer among older men. Conventional chemotherapy has proven to be not effective enough in battling it due to its high systemic toxicity and low selectivity. An alternative method of cancer treatment known as photodynamic therapy (PDT) has been shown to be effective. It is not without its faults either: one of the issues it’s been known to have is the insufficient selectivity of photosensitizer accumulation in tumor tissues. Recent studies, however, seem to indicate that introducing a PSMA-targeted moiety into photosensitizer might prove to be a solution to this problem. The present paper is concerned with synthesis of PSMA-targeted 131- and 152-substituted chlorin e6 conjugates and their biological characteristics. Our data suggests that the developed conjugates show potential as targeted agents for photodynamic therapy.


2014 ◽  
Vol 2 (03) ◽  
pp. 21-29
Author(s):  
Malay K. Samanta ◽  
Satendra Kumar Dubey ◽  
Priyanka Mishra

Novel approaches to drug delivery and formulation using nanotechnology are revolutionizing the future of medicine. The application of nanotechnology in medicine is offering many exciting possibilities in healthcare. Engineered nanoparticles and conjugation of monoclonal antibodies with anticancer drug Docetaxel have the potential to revolutionize the diagnosis and the therapy of its diseases, particularly by targeted delivery of anticancer drugs and imaging contrast agents. Prostate cancer, the second most common cancer in men, represents one of the major epidemiological problems, especially for patients in the advanced age. There is a substantial interest in developing therapeutic options for treatment of prostate cancer based on use of nanocarriers with the conjugation of drug and antibody, to overcome the lack of specificity of conventional chemotherapeutic agents as well as for the early detection of precancerous and malignant lesions. In this article, we highlight on the recent development of bioconjugation of drug with nanotechnology strategies adopted for the management of prostate cancer. In particular, the combination of targeted and controlled-release polymer nanocarriers have worked against prostate specific membrane antigen, a promising targeted Docetaxel-loaded nanoparticles, which can be validated for use in the prostate cancer therapy. However, several limitations facing nanoparticle delivery to solid tumors, such as heterogeneity of intratumoural barriers and vasculature, cytotoxicity and or hypersensitivity reactions to currently available cancer nanomedicines, and the difficult in developing targeted nanoparticles with optimal biophysicochemical properties, should be still addressed for successful tumor eradication.


2011 ◽  
Vol 108 (5) ◽  
pp. 1850-1855 ◽  
Author(s):  
Shanta Dhar ◽  
Nagesh Kolishetti ◽  
Stephen J. Lippard ◽  
Omid C. Farokhzad

2004 ◽  
Vol 171 (4S) ◽  
pp. 284-284
Author(s):  
Yi Lu ◽  
Jun Zhang ◽  
Ben Beheshti ◽  
Ximing J. Yang ◽  
Syamal K. Bhattacharya ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document